Our work supportsinvestigating S1PR1 antagonists as a clinical approach to mitigate opioid-induced adverseeffects and the repurposing of the functional S1PR1 antagonist FTY720, which is alreadyFDA-approved for multiple sclerosis, as an opioid adjunct. This evidence concerns the gene S1PR1 and multiple sclerosis.